SCHEMBL16127704

SCHEMBL16127704

O=C(Nc1ccccc1S(=O)(=O)N1CCOCC1)c1ccc(F)cc1F

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCL3 P20749 1/20 0.58
▸ POLB P06746 1/20 0.57
▸ KMT2A Q03164 2/20 0.56
▸ LMNA P02545 3/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.55
▸ ENPP2 Q13822 2/20 0.54
▸ TSHR P16473 2/20 0.53
▸ ALB P02768 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ CREBBP Q92793 2/20 0.51
▸ USP2 O75604 1/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ CNR1 P21554 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16088765 0.89 POLB (0.60) POLBKMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL16088763 0.89 MAPT (0.62) BCL3POLBKMT2ALMNAMAPK1
SCHEMBL16127833 0.84 POLB (0.63) POLBKMT2ALMNAALDH1A1TSHR
SCHEMBL16088783 0.83 HTT (0.64) KMT2ALMNASMN1; SMN2ALDH1A1ENPP2
SCHEMBL16127703 0.81 ALDH1A1 (0.70) POLBKMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL16088766 0.79 LMNA (0.68) POLBKMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL28157282 0.77 MAPT (0.52) BCL3LMNAMAPK1SMN1; SMN2ALDH1A1
SCHEMBL16088776 0.77 L3MBTL1 (0.62) BCL3POLBKMT2AMAPK1SMN1; SMN2
SCHEMBL17531739 0.76 CCR8 (0.66) POLBKMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL17538596 0.76 ALB (0.67) KMT2ALMNASMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968330-B1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS SCRIPPS RESEARCH INST (US) 2021-09-29 — — EP disclosed
US-11045476-B2 Compounds and methods for inducing chondrogenesis THE SCRIPPS RESEARCH INSTITUTE (US) 2021-06-29 — — US disclosed
US-20200188407-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE SCRIPPS RESEARCH INSTITUTE 2020-06-18 — — US disclosed
US-9452170-B2 Compounds and methods for inducing chondrogenesis THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-09-27 — — US disclosed
US-9452170-B2 Compounds and methods for inducing chondrogenesis THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-09-27 — — US disclosed
US-20160045514-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-02-18 — — US disclosed
US-20160045514-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-02-18 — — US disclosed
WO-2014151953-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11045476-B2 Compounds and methods for inducing chondrogenesis COL2A1, BMP4, COL1A1 BCL3 1034/4885POLB 3187/4885KMT2A 3871/4885
US-20160045514-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS COL2A1, BMP4, COL1A1 BCL3 1034/4885POLB 3187/4885KMT2A 3871/4885
US-20200188407-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS COL2A1, BMP4, COL1A1 BCL3 1034/4885POLB 3187/4885KMT2A 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback